At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
digitoxin +2 moredrug
Likely dose
digitoxin 0.05mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Digitoxin to Treat Cystic Fibrosis
In Brief
A Phase 2 clinical trial evaluating digitoxin and placebo for Cystic Fibrosis. Completed, enrolled 24 participants across 1 site.
Detailed Summary
This study will measure the inflammatory effects of digitoxin on IL-8 and neutrophil counts in induced sputum in stable Cystic Fibrosis (CF) patients and the pharmacokinetics of digitoxin in serum. Funding Source-FDA OOPD
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2008
Enrollment StartAug 2010
Primary CompletionAug 2016
TodayJul 2026
First PostedOct 31, 2008
Enrollment StartAug 1, 2010
Primary CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 6 yearsPosted 17.7 years ago
Interventions
digitoxindrug
0.05mg tabs, once daily for 28 days
digitoxindrug
0.1mg pills, once daily for 28 days.
placeboother
pill taken once daily for 28 days